About us

Graham Pockley is the CEO of multimmune GmbH, Munich, Emeritus Professor of Immunobiology and the former Director of the John van Geest Cancer Research Centre at Nottingham Trent University, UK, and Chief Scientific Officer (interim) of Alphageneron Pharmaceuticals Inc. USA. He was also the Founder and CEO of the flow cytometry resource Chromocyte, the assets iof which have now been acquired by Biocompare .

His career has focussed on the development of new immunotherapeutic strategies for treating aggressive and 'orphan' cancers, and new approaches for analysing and interpreting complex datasets and defining new biomarkers of disease presence, status and response to therapy in patients with cancer.

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists'​ (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics ('theranostics').

Graham has extensive experience at the interface of academia and translational research and can provide a broad range of insights and advice in a number of areas and disciplines:

Specialties:

• Cancer immunotherapies

• Natural killer (NK) cell cancer therapeutics

• Anrtibody-based cancer therapeutics

• Cancer theranostics

• Immunoregulatory mechanisms in health and disease

• Immunobiology of heat shock (stress) proteins

• Multi-parameter flow cytometry

• Flow cytometry functional assays

• Immunoassay development

• Cell-based assays